CRSP
CRISPR Therapeutics AGCRISPR Therapeutics AG reported revenue of $3.51M in its most recent fiscal year, down 90.6% on the year before. It kept -16569.8% of that as net income, and generated -$345.93M of free cash flow. Figures below are compared against other companies classified under Biological Products, (No Diagnostic Substances).
Grades vs. industry
Growth
| Metric | Company | Industry median | Rank |
|---|---|---|---|
Revenue growth (YoY) Latest fiscal year revenue vs. the year before. | -90.6% | 20.0% | — |
Revenue growth (3y) Annualized revenue growth over three fiscal years. | 43.1% | 14.6% | — |
Revenue growth (5y) Annualized revenue growth over five fiscal years. | 37.3% | 18.0% | — |
EPS growth (YoY) Diluted EPS vs. the prior fiscal year. | Not reported | 53.1% | — |
EPS growth (3y) Annualized diluted EPS growth over three fiscal years. | Not reported | 5.5% | — |
EPS growth (5y) Annualized diluted EPS growth over five fiscal years. | Not reported | 5.4% | — |
Free cash flow growth (YoY) Operating cash flow less capital expenditure, vs. prior year. | Not reported | -24.7% | — |
Free cash flow growth (3y) Annualized free cash flow growth over three fiscal years. | Not reported | 6.8% | — |
“Not reported” means the company did not tag this figure in its filing, not that the value is zero. Nothing here is ranked: this company reported an operating loss several times its revenue, so it is left out of its industry’s comparisons and does not count toward the medians shown. Its own figures are exactly as filed.
Profitability
| Metric | Company | Industry median | Rank |
|---|---|---|---|
Gross margin Gross profit as a share of revenue. Often unreported. | Not reported | 74.3% | — |
Operating margin Operating income as a share of revenue. | -18933.6% | -19.1% | — |
Net margin Net income as a share of revenue. | -16569.8% | -17.7% | — |
Free cash flow margin Free cash flow as a share of revenue. | -9855.5% | -22.3% | — |
Return on equity Net income divided by shareholder equity. | -30.3% | -16.5% | — |
Return on assets Net income divided by total assets. | -25.7% | -8.0% | — |
Return on invested capital After-tax operating profit over debt plus equity less cash. | -33.3% | -13.0% | — |
“Not reported” means the company did not tag this figure in its filing, not that the value is zero. Nothing here is ranked: this company reported an operating loss several times its revenue, so it is left out of its industry’s comparisons and does not count toward the medians shown. Its own figures are exactly as filed.
Financial health
| Metric | Company | Industry median | Rank |
|---|---|---|---|
Debt to equity Total debt divided by shareholder equity. | 0.00x | 0.29x | — |
Current ratio Current assets over current liabilities. | 13.32x | 3.75x | — |
Quick ratio Current assets excluding inventory, over current liabilities. | 13.32x | 3.34x | — |
Interest coverage Operating income divided by interest expense. | Not reported | 0.52x | — |
Net debt to EBITDA Net debt over derived EBITDA. EBITDA is not a GAAP tag; it is computed. | Not reported | -1.02x | — |
“Not reported” means the company did not tag this figure in its filing, not that the value is zero. Nothing here is ranked: this company reported an operating loss several times its revenue, so it is left out of its industry’s comparisons and does not count toward the medians shown. Its own figures are exactly as filed.
Debt figures can be understated where a filer splits borrowings across XBRL tags this site does not match.
Insider activity
Trades reported by officers, directors and 10% shareholders on SEC Form 4. None of the last 25 reported transactions were open-market purchases — grants, option exercises and sales make up the majority of insider filings at most companies.
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Oct 19, 2026 | Kulkarni Samarth Chief Executive Officer | Open-market sale | 47,837 | $49.78 | $2.38M |
| Oct 19, 2026 | Silver Andrew Jacob Chief Financial Officer | Grant or award(derivative) | 25,000 | $0.00 | $0.00 |
| Oct 16, 2026 | Kulkarni Samarth Chief Executive Officer | Option exercise | 100,000 | — | — |
| Oct 16, 2026 | Kulkarni Samarth Chief Executive Officer | Option exercise(derivative) | 100,000 | — | — |
| Oct 14, 2026 | George Simeon Director | Open-market sale | 14,514 | $49.63 | $720.4K |
| Oct 14, 2026 | George Simeon Director | Option exercise | 30,000 | $14.00 | $420.0K |
| Oct 14, 2026 | Kulkarni Samarth Chief Executive Officer | Open-market sale | 4,098 | $49.26 | $201.9K |
| Oct 14, 2026 | KASINGER JAMES R. General Counsel and Secretary | Open-market sale | 1,040 | $49.26 | $51.2K |
| Oct 14, 2026 | George Simeon Director | Option exercise(derivative) | 30,000 | $0.00 | $0.00 |
| Oct 13, 2026 | KASINGER JAMES R. General Counsel and Secretary | Option exercise(derivative) | 2,113 | — | — |
| Oct 13, 2026 | Kulkarni Samarth Chief Executive Officer | Option exercise | 8,333 | — | — |
| Oct 13, 2026 | Kulkarni Samarth Chief Executive Officer | Option exercise(derivative) | 8,333 | — | — |
| Oct 13, 2026 | KASINGER JAMES R. General Counsel and Secretary | Option exercise | 2,113 | — | — |
| Oct 6, 2026 | KASINGER JAMES R. General Counsel and Secretary | Open-market sale | 1,990 | $60.04 | $119.5K |
| Oct 6, 2026 | KASINGER JAMES R. General Counsel and Secretary | Option exercise | 1,990 | $13.62 | $27.1K |
| Oct 6, 2026 | KASINGER JAMES R. General Counsel and Secretary | Option exercise(derivative) | 1,990 | $0.00 | $0.00 |
| Sep 22, 2026 | KASINGER JAMES R. General Counsel and Secretary | Open-market sale | 10,400 | $60.24 | $626.5K |
| Sep 22, 2026 | KASINGER JAMES R. General Counsel and Secretary | Option exercise | 10,400 | $13.62 | $141.6K |
| Sep 22, 2026 | KASINGER JAMES R. General Counsel and Secretary | Option exercise(derivative) | 10,400 | $0.00 | $0.00 |
| Sep 17, 2026 | Behbahani Ali Director | Open-market sale | 13,679 | $57.09 | $780.9K |
| Sep 17, 2026 | Behbahani Ali Director | Option exercise | 30,000 | $14.00 | $420.0K |
| Sep 17, 2026 | Behbahani Ali Director | Option exercise(derivative) | 30,000 | $0.00 | $0.00 |
| Aug 7, 2026 | Prasad Raju Chief Financial Officer | Gift | 750 | $0.00 | $0.00 |
| Aug 6, 2025 | Behbahani Ali Director | Other | 60 | $0.00 | $0.00 |
| Aug 6, 2025 | Behbahani Ali Director | Other | 15 | $0.00 | $0.00 |
A dash under price or value means none was reported, which is normal for grants and gifts — it does not mean the shares were free. Option exercises and awards are compensation arriving on a schedule, not a judgement about the stock.
Annual financials
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.51M | $37.31M | $371.21M | $1.20M | $914.96M | $719.0K | $289.59M | $3.12M | $41.00M | $5.16M |
| Operating income | -$664.57M | -$466.57M | -$222.54M | -$673.16M | $373.53M | -$354.44M | $46.74M | -$158.94M | -$64.65M | -$68.13M |
| Net income | -$581.60M | -$366.25M | -$153.61M | -$650.17M | $377.66M | -$348.87M | $66.86M | -$164.98M | -$68.36M | -$23.18M |
| EPS (diluted) | -$6.47 | -$4.34 | -$1.94 | -$8.36 | $4.70 | -$5.29 | $1.17 | -$3.44 | -$1.71 | n/c |
| Operating cash flow | -$345.01M | -$142.77M | -$260.38M | -$495.74M | $538.97M | -$238.37M | $56.68M | -$96.24M | -$70.09M | -$52.86M |
| Capital expenditure | $914.0K | $1.90M | $9.47M | $37.19M | $81.70M | $18.36M | $6.68M | $2.77M | $7.81M | $3.02M |
| Free cash flow | -$345.93M | -$144.68M | -$269.85M | -$532.93M | $457.27M | -$256.72M | $49.99M | -$99.01M | -$77.91M | -$55.88M |
| Total assets | $2.27B | $2.24B | $2.23B | $2.24B | $2.75B | $1.83B | $1.07B | $489.02M | $271.35M | $344.96M |
| Shareholder equity | $1.92B | $1.93B | $1.88B | $1.88B | $2.40B | $1.66B | $939.42M | $392.19M | $187.83M | $232.85M |
| Total debt | $0.00 | — | — | — | — | — | — | — | — | — |
| Cash | $347.56M | $298.26M | $389.48M | $211.88M | $923.03M | $1.17B | $943.77M | $456.65M | $239.76M | $315.52M |
A dash means the figure was not tagged in that year’s filing. It does not mean zero. Figures reflect the most recent filing covering each period, so restated years show their restated values.
n/c marks per-share figures that are not comparable. Companies report each year as their filings stated it, and an annual report restates only its two prior years — so after a stock split, older years remain on the pre-split share count. Totals above are unaffected.
Source
Figures come from CRISPR Therapeutics AG’s filings with the SEC, as submitted in XBRL. The most recent annual figures are from a 10-K filed Feb 12, 2026. View filings on EDGAR.